Sanofi Pasteur has launched an ambitious mid-stage clinical trial for an experimental new vaccine that will attempt to thwart the rising risk of hospital-acquired Clostridium difficile infection.
Medarex and Massachusetts Biologic Laboratory will share an upfront payment of $60 million and up to $165 million in milestones from Merck, which is licensing an antibody they discovered for C.
Sanofi-Pasteur has launched a clinical trial in Thailand to test a tetravalent vaccine for dengue fever, the world's second most common tropical disease in children. Adding to the urgency for the
Optimer Pharmaceuticals' stock surged on news that the company's anti-infective drug OPT-80 outperformed ViroPharma's Vancocin in a late-stage trial. Vancocin is currently the only approved treatment